Outlook Therapeutics (OTLK) said Tuesday the resubmission of its biologics license application for ONS-5010, an investigational ophthalmic formulation for the treatment of wet age-related macular degeneration, was accepted by the US Food and Drug Administration.
The agency's classification of the application as a class 2 review means that there will be a six-month review period from the date of resubmission, the company said.
Outlook said the FDA has set a Prescription Drug User Fee Act goal date of Aug. 27, by which it must respond.
The company also said it plans to brand the treatment as Lytenava in the US if approved by the agency, adding that it expects to receive 12 years of regulatory exclusivity.
The shares were up over 9% in recent trading.
Price: 1.25, Change: +0.11, Percent Change: +9.56
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。